Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EUDA Health Holdings Limited (EUDAW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. EUDA files current reports on Form 6-K under the Securities Exchange Act of 1934, which furnish information about material events, financing transactions, and other matters related to its Singapore-based health technology business and Southeast Asian digital healthcare ecosystem.
In these filings, EUDA has described entering into an At The Market Offering Agreement that allows it to issue and sell ordinary shares through a sales agent, as well as a convertible promissory note purchase agreement under which notes are convertible into newly issued ordinary shares at a discount to the trading price, subject to specified conditions. The company’s 6-K reports also reference a shelf registration statement on Form F-3, with certain agreements and legal opinions incorporated by reference into that registration statement and related prospectus supplements.
Filings on this page may also include reports of press releases furnished as exhibits, such as announcements about Nasdaq listing delinquency letters tied to delayed Form 10-K and Form 10-Q filings. While those periodic reports are filed separately, the 6-K disclosures explain the listing rule framework and the company’s responses.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms in documents like Form 6-K, describe the structure of at-the-market offerings and convertible notes, and clarify how these instruments relate to EUDA’s ordinary shares and warrants. Users can review new filings as they appear on EDGAR, see how specific agreements affect EUDAW-related securities, and use AI-generated insights to navigate complex legal and financing language more efficiently.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Limited reports a new agreement with its institutional investor around an existing convertible note. The investor originally agreed to purchase up to
EUDA Health Holdings Ltd. (Nasdaq: EUDA) has filed a Form 424(b)(5) prospectus supplement to register up to 5,000,000 ordinary shares underlying a US$10 million one-year convertible note to be sold to Indigo Capital LP in a registered-direct transaction. Notes are issued at a 10 % original-issue discount (net cash ≈ US$9 million; estimated net proceeds after expenses ≈ US$8.98 million) and convert at 85 % of the share’s Nasdaq close on the conversion date, capped at 4.99 % beneficial ownership. A 5-day closing bid below US$2.00 constitutes an “Early Default,” accelerating repayment or conversion; no interest accrues. No public market will exist for the notes.
The financing adds to an already highly dilutive capital structure: 37.16 million shares outstanding, 8.9 million warrants and other convertibles. FY-2024 results showed a US$15.4 million net loss, US$3.4 million working-capital deficit and only US$0.2 million cash. The auditor issued a going-concern warning and management cited material-control weaknesses. Proceeds are earmarked for working capital, M&A and general corporate purposes.
EUDA is pivoting from low-demand medical clinics to wellness services after acquiring CK Health (2.2 % of 2024 revenue) and partnering for stem-cell packages. Two large shareholders control ~53 % of equity, and resale registration rights could pressure the stock. Investors face execution, dilution, and delisting risks offset by near-term liquidity from the note.
FAQ
What is the current stock price of EUDA Health Holdings (EUDAW)?
